🔴 MBX Biosciences is trading 5% down today amid broader market and biotech weakness

MBX Biosciences is trading at $47.84, down 5.19%, with broader risk-off sentiment the likeliest context for the decline.

• No clear company-specific news explains the October 23 decline. A recent announcement appointed Peter Radovich as an independent director, but available reporting does not link it to the move.
• Major indices are lower, and the supplied sector context also shows biotech weakness.
• The decline follows a -6.43% close on October 22, extending the recent decline.